These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27723281)

  • 1. Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab.
    Hoffman RW; Merrill JT; Alarcón-Riquelme MM; Petri M; Dow ER; Nantz E; Nisenbaum LK; Schroeder KM; Komocsar WJ; Perumal NB; Linnik MD; Airey DC; Liu Y; Rocha GV; Higgs RE
    Arthritis Rheumatol; 2017 Mar; 69(3):643-654. PubMed ID: 27723281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
    Merrill JT; van Vollenhoven RF; Buyon JP; Furie RA; Stohl W; Morgan-Cox M; Dickson C; Anderson PW; Lee C; Berclaz PY; Dörner T
    Ann Rheum Dis; 2016 Feb; 75(2):332-40. PubMed ID: 26293163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
    Isenberg DA; Petri M; Kalunian K; Tanaka Y; Urowitz MB; Hoffman RW; Morgan-Cox M; Iikuni N; Silk M; Wallace DJ
    Ann Rheum Dis; 2016 Feb; 75(2):323-31. PubMed ID: 26338095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials.
    Rovin BH; Dooley MA; Radhakrishnan J; Ginzler EM; Forrester TD; Anderson PW
    Lupus; 2016 Dec; 25(14):1597-1601. PubMed ID: 27220348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.
    Yao Y; Richman L; Higgs BW; Morehouse CA; de los Reyes M; Brohawn P; Zhang J; White B; Coyle AJ; Kiener PA; Jallal B
    Arthritis Rheum; 2009 Jun; 60(6):1785-96. PubMed ID: 19479852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
    Merrill JT; Shanahan WR; Scheinberg M; Kalunian KC; Wofsy D; Martin RS
    Ann Rheum Dis; 2018 Jun; 77(6):883-889. PubMed ID: 29563108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus.
    Witcher J; Fleischmann R; Chindalore VL; Hansen RJ; Hu L; Radtke D; Voelker J; Gomez E; McColm J
    Br J Clin Pharmacol; 2016 May; 81(5):908-17. PubMed ID: 26648084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study.
    Tanaka Y; Takeuchi T; Akashi N; Takita Y; Kovacs B; Kariyasu S
    Mod Rheumatol; 2017 Mar; 27(2):284-291. PubMed ID: 27471815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid.
    Lauwerys BR; Hachulla E; Spertini F; Lazaro E; Jorgensen C; Mariette X; Haelterman E; Grouard-Vogel G; Fanget B; Dhellin O; Vandepapelière P; Houssiau FA
    Arthritis Rheum; 2013 Feb; 65(2):447-56. PubMed ID: 23203821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
    Furie R; Khamashta M; Merrill JT; Werth VP; Kalunian K; Brohawn P; Illei GG; Drappa J; Wang L; Yoo S;
    Arthritis Rheumatol; 2017 Feb; 69(2):376-386. PubMed ID: 28130918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus.
    Carter LM; Isenberg DA; Ehrenstein MR
    Arthritis Rheum; 2013 Oct; 65(10):2672-9. PubMed ID: 23839909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus.
    Petri M; Fu W; Ranger A; Allaire N; Cullen P; Magder LS; Zhang Y
    BMC Med Genomics; 2019 Jan; 12(1):4. PubMed ID: 30626389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
    Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
    Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial.
    Genovese MC; Bojin S; Biagini IM; Mociran E; Cristei D; Mirea G; Georgescu L; Sloan-Lancaster J
    Arthritis Rheum; 2013 Apr; 65(4):880-9. PubMed ID: 23359344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
    Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O
    Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
    Wang H; Li T; Chen S; Gu Y; Ye S
    Arthritis Rheumatol; 2015 Dec; 67(12):3190-200. PubMed ID: 26245802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 'That Obscure Object of Desire': in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians.
    Sanchez-Niño MD; Ortiz A
    Nephrol Dial Transplant; 2015 Mar; 30(3):394-400. PubMed ID: 24914092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further thoughts about the ILLUMINATE studies of tabalumab in SLE.
    Isenberg D
    Ann Rheum Dis; 2016 Feb; 75(2):e11. PubMed ID: 26530320
    [No Abstract]   [Full Text] [Related]  

  • 20. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial.
    Cardiel MH; Tumlin JA; Furie RA; Wallace DJ; Joh T; Linnik MD;
    Arthritis Rheum; 2008 Aug; 58(8):2470-80. PubMed ID: 18668592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.